Fig. 5: NRAS ASO-1 treatment in combination with FGFR2 and CDK4 inhibition has synergistic potential. | Communications Medicine

Fig. 5: NRAS ASO-1 treatment in combination with FGFR2 and CDK4 inhibition has synergistic potential.

From: Suppression of NRAS-mutant melanoma growth with NRAS-targeting Antisense Oligonucleotide treatment reveals therapeutically relevant kinase co-dependencies

Fig. 5

a–d Dual treatment with 20 nM of NRAS ASO-1 and the FGFR2 inhibitor pemigatinib (Pemi, a, b, 40 nM –2500 nM), respectively the CDK4 inhibitor palbociclib (Palb, c, d, 40 nM–2500 nM) caused synergistic effects in the D04 (a + c) and MM415 (b) cell lines after 5 days of treatment. Dual treatment with NRAS ASO-1 and Palbociclib caused additive overall effects in MM415 (d), with synergism in the lowest Palbociclib dose regimen (40 nM). Dual treatment with 20 nM of NRAS ASO-1 and the RET inhibitor selpercatinib (Selp, e, f, 49 nM - 6250 nM), caused antagonistic effects in the D04 (e) and MM415 (f) cell lines after 5 days of treatment. Dose response curves show NRAS ASO-1 treatment (blue), pemigatinib or palbociclib treatment (yellow) and dual treatment (red). Synergism of dual cell growth inhibition is shown as bar graphs and determined by the HSA synergy score (n = 2).

Back to article page